Safety Evaluation Study of Repaglinide Loaded Polymeric Nanoparticles Formulation

Nanotechnology has facilitated noteworthy advances in the field of medicine. Whereas a number of nanoparticle drug combinations are at various stages of preclinical or clinical assessment, the careful assessment of their toxic response is the need of the hour. This study aims to evaluate the safety profile of Poly (lactic-co-glycolide) (PLGA) nanoparticles containing the antidiabetic drug, Repaglinide (Rg) for its effective oral delivery. The Rg loaded polymeric nanoparticles were synthesized and characterized for particle size, drug content, entrapment efficiency and compatibility. The nanoparticles were then fed to wistar albino rats for a duration of 21 days, to assess the adversities of nanoparticles on various organs in the rats. Along with the biochemical and haematological studies, histopathological examination was done to monitor intravascular effects, and they were also tested for haemocompatibility and cytotoxicity. MTT measurement reveals that the nanoparticle treated cells are 70-80% viable. The test drug did not produce any significant histopathological changes in the cryoarchitecture of any organ studied at various dose levels. Hence our data indicates that these polymeric nanoparticles are nontoxic and provide a suitable platform for the oral delivery of the antidiabetic agent.